Under the multi-year research collaboration, ComGenex will apply its proprietary Matrix technology, using in silico tools to expedite the design of targeted compound libraries. In addition, ComGenex will synthesize and purify the compounds using its high throughput synthesis and purification platform for biological evaluation at Roche. The program will require close collaboration between ComGenex and Roche scientists, something that has already been a key element of success in other ComGenex collaborations. "This collaboration allows us to demonstrate the power of our integrated technologies to support drug discovery projects of world leading companies like Hoffmann-La Roche. We expect the integration of our technologies with Roche's comprehensive screening capabilities will accelerate this research project significantly," said Dr Laszlo Urge, chief executive officer of ComGenex.